02:43 AM EDT, 09/18/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) unit Alexion said Friday the US Food and Drug Administration granted priority review to its application for efzimfotase alfa to treat hypophosphatasia in patients aged two years or older. The biologics license application is backed by a late-stage clinical program comprising the Hickory, Mulberry and Chestnut studies, in which efzimfotase alfa showed favorable safety and tolerability profiles across all trials. The Prescription Drug User Fee Act action date is expected during the first half of 2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.